RGC

Long-Term 2.1Long-Term 2.0Long-Term 1.0

$32.06+$10.02 (+45.5%)at exit

Alfred's Verdict

Ask Alfred

Alfred picked RGC on 2026-01-02 at $22.04 and sold on 2026-04-02 at $32.06 after Signal faded, resulting in a 45.5% gain.

Pick Details

Pick Date2026-01-02

Entry Price$22.04

CategoryMomentum

RankExited

Exit Date2026-04-02

Alfred has exited this position

Price Chart

258 trading days

BuySellBacktest / Live

Open full chart on TradingView

Post-Trade Analysis

Exited 2026-04-02

What Happened

Alfred re-entered RGC after a painful stop-loss exit in November, betting on the biotech's recovery amid continued healthcare innovation momentum. The models detected renewed upside potential in this volatile specialty drug developer, leading to another significant 33% position despite the company's continued losses. After three months, the original bullish signals weakened and Alfred exited with a solid gain.

The Numbers

- Entry: $22.04 on 2026-01-02 | Exit: $32.06 on 2026-04-02 - Result: +45.5% (+$10,070.10) - Exit trigger: Signal faded

In Hindsight

Alfred's exit timing was premature—RGC continued climbing to $32.24 by April 13th, leaving an additional 4.7% on the table. However, given this stock's extreme volatility (it traded between $0.09-$83.60 over the prior year), the disciplined exit when signals faded was prudent risk management. The company's fundamentals remain deeply troubled with no revenue and massive losses.

Lessons

- Alfred's models can successfully navigate biotech volatility by focusing on momentum rather than fundamentals, turning a previous loss into redemption - Early exit discipline protects gains in speculative plays, even if it means missing some upside in highly unpredictable stocks

Original Thesis

2026-01-02

Position Exited — Signal faded This was Alfred's thesis when the position was opened.

Why Alfred Picked This

RGC represents a high-risk biotechnology play amid the current surge in healthcare innovation and specialty drug development. Despite generating a neutral signal, Alfred allocated 33% of the portfolio to this position, suggesting the models detect significant upside potential that isn't reflected in traditional metrics. With a negative $0.01 earnings per share and return on equity of -54.8%, this is purely a speculative bet on future drug development success.

What's Working

- Massive volatility creates opportunity for algorithmic trading strategies, with the stock trading between $0.09 and $83.60 over the past year and a beta of 2.022 - The $16 billion market cap suggests institutional backing despite current losses, indicating confidence in the company's drug pipeline - Position sizing at 33% allocation signals Alfred's models detect strong momentum or catalyst potential not visible in current fundamentals

What to Watch

- Extreme financial distress with negative returns across all profitability metrics (ROE -54.8%, ROA -33.2%) could lead to funding difficulties or dilutive equity raises - Massive price volatility from $83.60 to $0.09 indicates this stock can lose 99% of its value quickly if drug trials fail or regulatory approval is denied